CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,014 enrolled
Drug / intervention
Genesys HTAdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01197547
NCT01197547N/ACompleted

Genesys HTA Post Approval Registry A Multi-center, Single-arm, Prospective Registry of the Genesys HTA System for the Treatment of Menorrhagia

Minerva Surgical, Inc.·interventional·Posted Sep 9, 2010·Updated Mar 26, 2021

In Brief

A clinical study evaluating Genesys HTA for Menorrhagia. Completed, enrolled 1,014 participants across 19 sites.

Detailed Summary

This is a clinical registry of an FDA approved device system called the Genesys Hydro ThermAblatorTM (HTA) system (Boston Scientific). The HTA system's intended use is to be inserted, by a trained physician, into the uterus, where it will fill and circulate fluid that is warm enough to change the characteristics of the uterine lining. This is done with the anticipated result of improving menstrual bleeding symptoms. The purpose of this FDA-mandated registry is to obtain clinical experience on the use the Genesys HTA™ system, under normal clinical conditions, and document its safety and technical reliability.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMenorrhagia
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 9, 2010
Enrollment StartNov 1, 2010
Primary CompletionFeb 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 15.8 years ago

Interventions

Genesys HTAdevice

Genesys HTA Endometrial Ablation